Elevated serum IL6 has been demonstrated to associate with clinical outcome in several cancers, including breast cancer and prostate cancer where IL6 has been shown to have pleiotropic properties (Fisher et al., 2014). This evidence concerns the gene IL6 and breast carcinoma.